Lack of Suitable Resources Limiting Ebola Diagnoses in West Africa
Poor logistics and low trained staff numbers are two of the greatest limitations to providing a sufficient molecular diagnostic capacity for Ebola in West Africa, where only 56% of cases are described as confirmed and the remaining cases are probable or suspected, according to an analyst with research and consulting firm GlobalData.
Andrew S. Thompson, Ph.D., GlobalData’s Senior Analyst covering in vitro diagnostics, states that if the number of diagnosed Ebola cases in West Africa increased to 10,000 per week, as recently predicted by the World Health Organization, local diagnostic laboratories would need to be capable of processing at least 3400 specimens per day collectively, to support the number of positive tests and repeat negative tests expected.
Thompson says: “While modern molecular diagnostic testing is the most sensitive and precise way to detect the Ebola virus, it is complex and expensive to perform. It is therefore extremely challenging to implement this technology in poorer regions of the world, where the healthcare infrastructure is inadequate, or even nonexistent.
“At present, there continue to be only a few established diagnostic facilities in West Africa, and while donor countries are increasingly providing mobile laboratory facilities, these can only slightly narrow the gap in the testing capacity.”
The analyst notes that while the shortage of trained staff can be filled by deploying skilled scientists from outside the region, poor logistics is a more difficult problem to solve, as the reagents used for testing require constant refrigeration during their movement through the supply chain.
Thompson continues: “One solution might be to introduce molecular diagnostics suitable for the African environment. These could include reagents that are not dependent upon refrigeration, as well as instruments that are low-cost, self-powered, simple to use, and can be implemented quickly on short notice by governments in the region.
“This approach would provide a more robust model for responding to sporadic emergencies than the current approach, which depends on coordinating a global response and typically lags behind the first occurrence of the outbreak.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance